impact biomedical inc 2025年季度报告

FORM10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period endedSeptember 30,2025 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 333-275062Commission file number IMPACT BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) 85-3926944 1400 Broadfield Blvd.,Suite 130,Houston,TX,77084(Address of principal executive offices) (281)415-6576(Registrant’s telephone number, including area code) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Date File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files)Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See definitions of “large accelerated filer”, “accelerated filer”, “smaller reportingcompany” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Accelerated filer☐Non-accelerated filer☒Smaller reporting company☒ Emerging growth company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes☐No☒ Securities registered pursuant to Section 12(b) of the Act: As of October 27, 2025 there were104,621,231shares of the registrant’s common stock, $0.001par value, outstanding. IMPACT BIOMEDICAL, INC.FORM 10-QTABLE OF CONTENTS PART IFINANCIAL INFORMATIONItem 1Condensed Consolidated Financial StatementsCondensed Consolidated Balance Sheets as of September 30, 2025 (Unaudited) and December 31, 20242Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2025 and2024 (Unaudited)3Condensed Consolidated Statement of Changes in Stockholders’ (Deficit) Equity for the nine months endedSeptember 30, 2025 and 2024 (Unaudited)4Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and 2024(Unaudited)5Notes to Interim Condensed Consolidated Financial Statements6Item 2Management’s Discussion and Analysis of Financial Condition and Results of Operations18Item 4Controls and Procedures22PART IIOTHER INFORMATION23Item 1Legal Proceedings23Item 1ARisk Factors23Item 2Unregistered Sales of Equity Securities and Use of Proceeds23Item 3Defaults upon Senior Securities23Item 4Mine Safety Disclosures23Item 5Other Information23Item 6Exhibits241 Table of Contents Table of Contents Impact BioMedical, Inc. and SubsidiariesCondensed Consolidated Statements of Operations(unaudited) Table of Contents Table of Contents Impact BioMedical, Inc. and SubsidiariesCondensed Consolidated Statements of Cash FlowsFor the Nine Months Ended September 30,(unaudited) Note 1.Nature of Operations and Basis of Presentation Nature of Operations Impact BioMedical, Inc., incorporated in the State ofNevadaonOctober 16, 2018(the “Company”, “Impact BioMedical”, “We”,“IBO”), discovers, confirms, and patents unique science and technologies which can be developed into new offerings in humanhealthcare and wellness in collaboration with external partners through licensing, co-development, joint ventures, and otherrelationships. By leveraging technology and new science with strategic partnerships, we provide advances in biopharmaceuticals, overthe counter direct to consumer wellness offerings, and drug discovery for the prevention, inhibition, and treatment of neurological,oncologic, and inflammatory diseases. In addition to our existing efforts, we continually search for, and evaluate, other potential newofferings to add to our portfolio. Our business model includes partnering and potentially direct sales for commercialization and distribution. Potential licensors anddevelopment partners include pharmaceutical, consumer packaged goods companies and others, who would commercialize IBOtechnologies in exchange for milestone, and royalty payments. Currently, our operations are conducted, and our assets are ownedthrough our principal subsidiaries: (i) Global BioLife, Inc. (“Global BioLife”), which was incorporated on April 14, 2017, (ii) ImpactBioLife Science, Inc. (“Impact BioLife”), which was inco